TWO IMPORTANT features of the epidemiology of systemic lupus erythematosus (SLE) have become apparent in recent years. First, probably because of increased awareness and testing, the incidence of SLE appears to have tripled to 5.56 per 100 000 population, with an estimated prevalence of 130 per 100 000.1 Second, although the survival of patients with SLE has markedly improved, with 10-year survival rates of over 80%,1,2 mortality is still substantial. More than a third of all SLE deaths occur among persons younger than 45 years, and annual mortality has increased 1.6-fold over the last 2 decades.3 Many more patients suffer considerable morbidity and loss of quality of life. The major role of accelerated or "premature" atherosclerotic cardiovascular and cerebrovascular disease (ASCVD) in the morbidity and mortality of patients with SLE is now well established. Recently, new research has provided important insights into the scope and mechanisms of atherosclerotic vascular disease in lupus. Defining these advances may improve awareness, enable a more informed and effective therapeutic approach, and hopefully lead to better patient outcomes.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 38
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.